Results 151 to 160 of about 13,539,459 (250)
Bovine herpesvirus 4 infections and bovine mastitis
Mastitis is an often occurring disease in dairy cattle with an enormous economic impact for milk producers worldwide. Despite intensive research, which is historically based on the detection of bacterial udder pathogens, still around 20-35% of clinical cases of bovine mastitis have an unknown aetiology.
openaire +3 more sources
Manufacturing and clinical applications of non‐CAR‐T immune effector cells
Transfusion, EarlyView.
Thane Kubik +2 more
wiley +1 more source
ABSTRACT Consider human herpesvirus 6 (HHV‐6) in immunocompetent adults with viral meningitis when standard tests are negative. Qualitative CSF PCR requires cautious interpretation because it cannot exclude chromosomally integrated HHV‐6. Serial CSF improvement and rapid clinical recovery may support probable self‐limited infection and help avoid ...
Hatem M. Taha +5 more
wiley +1 more source
Multiple sclerosis, human herpesvirus 4 and thyroid collision tumor: A case report. [PDF]
Sirbu AM +5 more
europepmc +1 more source
Seroprevalence of equine herpesvirus‐1 (EHV‐1) and herpesvirus‐4 (EHV‐4) in Moroccan horse populations [PDF]
openaire +1 more source
ABSTRACT Idiopathic multicentric Castleman disease can rarely present with systemic inflammation and erosive seronegative polyarthritis. Awareness of this association helps prevent misdiagnosis and ensures appropriate immunosuppressive management based on clinicopathological and immunohistochemical correlation.
Birahim Lo +9 more
wiley +1 more source
Bovine Herpesvirus-4-Vectored Delivery of Nipah Virus Glycoproteins Enhances T Cell Immunogenicity in Pigs. [PDF]
Pedrera M +17 more
europepmc +1 more source
AIM: To detect the presence of bovine herpesvirus (BoHV) type 4 in New Zealand dairy cows with clinical metritis. METHODS: Serum samples taken from 92 dairy cows with clinical metritis, each from a different farm, were tested for the presence of ...
Melvin de Boer (15396575) +3 more
core
Real‐World Efficacy and Systemic Immune Modulation Upon Tralokinumab Treatment in Atopic Dermatitis
ABSTRACT Background Tralokinumab, an interleukin‐13 (IL‐13) monoclonal antibody, has shown clinical efficacy in randomized trials for moderate‐to‐severe atopic dermatitis (AD). This study aims to evaluate clinical and immunological outcome upon tralokinumab treatment in a real‐world cohort of patients with moderate‐to‐severe AD. Methods We recruited 81
Meslina Almaci +3 more
wiley +1 more source
Se describen los antecedentes y el estado actual de los anticuerpos monoclonales (AcM) anti-Rh(D). Estos AcM han dado lugar a una vía alternativa de producción de reactivos hemoclasificadores no dependientes de la inmunización deliberada de humanos ...
René A Rivero Jiménez
doaj

